9Bio

9Bio Therapeutics leverages its AI-guided structural biology platform to design tumor-specific, conditionally active cancer therapeutics. The platform distinguishes itself by modeling mutated cancer-causing proteins under the unique conditions of the tumor microenvironment (e.g., acidic pH), enhancing the cancer-specificity of engineered therapeutics by limiting the binding potential in healthy cell conditions. Initially, 9Bio focuses on hard-to-treat targets such as anti-PDL1, which is being developed as an antibody-drug conjugate (ADC), and CD44v6, a previously tested ADC that showed clinical efficacy but was discontinued due to toxicity. 9Bio’s approach improves safety and efficacy through cancer-cell specificity, and also reduces development costs, offering a competitive edge in the immuno-oncology space.